Biogen seeks FDA approval for Alzheimer’s drug; aims to be first to slow disease
Treatment with aducanumab reduced declines in memory, language, and activities of daily living performance, the drugmaker says.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
